THERANOVA-LIM : améliorer l’accès à l’information sur les traitements oraux pour les patients et les pharmaciens
Bulletin du Cancer · 2026
DOI: 10.1016/j.bulcan.2025.10.005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bulletin du Cancer, 2026. Verfasst von Marion Boucheteil und 12 weiteren Autor:innen. Beteiligte Einrichtung: Unité de pharmacie clinique, division de pharmacie hospitalière, centre hospitalier universitaire de Limoges, Limoges, France. Hauptthemen laut MEDLINE: Patient Satisfaction, Pharmacists, Antineoplastic Agents, Neoplasms. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Seagen Inc, AstraZeneca PLC, National League Against Cancer.
Abstract (Originalsprache)
OBJECTIVES: To evaluate patient and pharmacist satisfaction with two information systems using QR codes to access information about oral cancer treatments. METHODS: THERANOVA-LIM (NCT04931329) was a prospective, descriptive, single-centre study of cancer patients receiving oral treatment. Patients were divided into two groups: one group using the information card and the other using the standard prescription with QR code. Patient satisfaction was assessed at 3 months using questionnaires. RESULTS: In all, 128 patients were included: 55 received a 'drug information card' and 73 a 'prescription with QR code'. The median age was 69 (37-90). The three most common cancers were breast (37.5%), prostate (14.1%) and brain (10.9%). The vast majority of patients had metastatic cancer (90%). The three most prescribed drugs were capecitabine (21.1%), ribociclib (11.7%) and temozolomide (11.7%). Patients presented the QR codes during medical consultations (25.0%), pharmacy visits (100%) and during home visits by nurses (25.0%). Both patients and professionals were satisfied with these new systems. Pharmacists felt that the prescription with a QR code was more useful for their daily practice in the pharmacy (P=0.02). CONCLUSIONS: QR code systems proved effective in providing information to patients and healthcare professionals. The QR code prescription appeared to be the most practical for pharmacy activities. TRIAL REGISTRATION NUMBER AND THE DATE OF REGISTRATION: ClinicalTrials.gov, NCT04931329. 2021-05-10.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Unité de pharmacie clinique, division de pharmacie hospitalière, centre hospitalier universitaire de Limoges, Limoges, France.
- Département d'oncologie médicale, centre hospitalier universitaire de Limoges, Limoges, France.
- Département d'hématologie, centre hospitalier universitaire de Limoges, Limoges, France.
- Département d'oncologie médicale, centre hospitalier universitaire de Limoges, Limoges, France. Electronic address: elise.deluche@chu-limoges.fr.
Förderung
- Seagen Inc
- AstraZeneca PLC
- National League Against Cancer
- Viatris Inc
- LEO Pharma A/S
Zitieren
APA
Boucheteil, M., Leobon, S., Baffert, K. A., Huet, S., Darbas, T., Le Brun-Ly, V., Pestre, J., Peyramaure, C., Thuillier, F., Venat, L., Jost, J., Touati, M., & Deluche, E. (2026). THERANOVA-LIM : améliorer l’accès à l’information sur les traitements oraux pour les patients et les pharmaciens. Bulletin du Cancer. https://doi.org/10.1016/j.bulcan.2025.10.005
Vancouver
Boucheteil M, Leobon S, Baffert KA, Huet S, Darbas T, Le Brun-Ly V, et al. THERANOVA-LIM : améliorer l’accès à l’information sur les traitements oraux pour les patients et les pharmaciens. Bulletin du Cancer. 2026. doi:10.1016/j.bulcan.2025.10.005
BibTeX
@article{Boucheteil2026,
author = {Boucheteil, Marion and Leobon, Sophie and Baffert, Kim-Arthur and Huet, Soline and Darbas, Tiffany and Le Brun-Ly, Valérie and Pestre, Julia and Peyramaure, Clémentine and Thuillier, Frédéric and Venat, Laurence and Jost, Jérémy and Touati, Mohamed and Deluche, Elise},
title = {THERANOVA-LIM : améliorer l’accès à l’information sur les traitements oraux pour les patients et les pharmaciens},
journal = {Bulletin du Cancer},
year = {2026},
doi = {10.1016/j.bulcan.2025.10.005}
}
EUVIMED